-
From IV drips to injection pens: Why more drugs can be given under the skin
One to two millilitres was once considered the practical limit for subcutaneous injections. Advances in drug formulations and delivery systems have since made larger volumes possible, says Uppsala University researcher Per Hansson. This is the second article in a Life Science Focus series on the shift towards subcutaneous drug administration.
-
Autoinjectors gain ground across therapeutic areas: “A huge trend”
Pharmaceutical companies are increasingly exploring subcutaneous treatments as an alternative to intravenous infusions, with the potential for home administration. Autoinjector manufacturer SHL Medical sees the greatest opportunities in oncology. This is the first in a Life Science Focus series exploring the shift towards subcutaneous drug administration.
-
Danish health minister: Europe must act on China
Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Minister Ida Auken also warns that Europe must act to keep pace with growing competition from China.
-
Camurus takes next step with Oczyesa – wins Canadian approval
Swedish pharmaceutical company Camurus has secured another marketing approval for its acromegaly treatment. Canada has now approved Oczyesa XR, which patients can inject themselves once a month.
-
Danish diabetes firm secures MDR approval: “It's not something that you just do”
After formerly obtaining a regulatory for patients over 18 years old, Hedia can now expand its support to pediatric care.
Get access to all content on Life Science Focus
No commitment or card information required
Already a subscriber? Log In
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement
Advertisement
Advertisement
BREAKING